

will be sent to all grantees after the awards are made.

### VII. Agency Contacts

*Program Office Contact:* Katherine Gray, U.S. Department of Health and Human Services, Administration for Children and Families, ACYF—Head Start Bureau, 330 C Street SW., Switzer Room 2211, Washington, DC 20447, Phone: 312-353-2260, E-mail: [kgray@acf.hhs.gov](mailto:kgray@acf.hhs.gov).

*Grants Management Office Contact:* Delores Dickenson, U.S. Department of Health and Human Services, Administration for Children and Families, ACYF—Head Start Bureau, 330 C Street SW., Switzer Room 2220, Washington, DC 20447, Phone: 202-260-7622, E-mail: [dedickenson@acf.hhs.gov](mailto:dedickenson@acf.hhs.gov).

### VIII. Other Information

Applicants will not be sent acknowledgements of received applications.

*Notice:* Beginning with FY 2006, the Administration for Children and Families (ACF) will no longer publish grant announcements in the **Federal Register**. Beginning October 1, 2005, applicants will be able to find a synopsis of all ACF grant opportunities and apply electronically for opportunities via: <http://www.Grants.gov>. Applicants will also be able to find the complete text of all ACF grant announcements on the ACF Web site located at: <http://www.acf.hhs.gov/grants/index.html>.

Dated: March 31, 2005.

**Joan E. Ohl,**

*Commissioner, Administration on Children, Youth and Families.*

[FR Doc. 05-7030 Filed 4-12-05; 8:45 am]

BILLING CODE 4184-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 2005N-0059]

#### Withdrawal of Approval of a New Animal Drug Application; Dichlorophene and Toluene Capsules

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is withdrawing approval of a new animal drug application (NADA) for dichlorophene and toluene capsules used in dogs and cats for removal of certain intestinal parasites. In a final rule published

elsewhere in this issue of the **Federal Register**, FDA is amending the animal drug regulations to remove portions reflecting approval of this NADA.

**DATES:** Withdrawal of approval is effective April 25, 2005.

**FOR FURTHER INFORMATION CONTACT:**

Pamela K. Esposito, Center for Veterinary Medicine (HFV-212), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 301-827-7818, e-mail: [pesposit@cvm.fda.gov](mailto:pesposit@cvm.fda.gov).

**SUPPLEMENTARY INFORMATION:** Natchez Animal Supply Co., 201 John R. Junkin Dr., Natchez, MS 39120, has requested that FDA withdraw approval of NADA 121-557 for THR Worm (dichlorophene and toluene) Capsules used in dogs and cats for removal of certain intestinal parasites. This action is requested because the product is no longer manufactured or marketed.

Therefore, under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10), redelegated to the Center for Veterinary Medicine (21 CFR 5.84), and in accordance with 21 CFR 514.115 *Withdrawal of approval of applications*, notice is given that approval of NADA 121-557 and all supplements and amendments thereto, is hereby withdrawn, effective April 25, 2005.

In a final rule published elsewhere in this issue of the **Federal Register**, FDA is amending the animal drug regulations to reflect the withdrawal of approval of this NADA.

Dated: March 31, 2005.

**Catherine P. Beck,**

*Acting Director, Center for Veterinary Medicine.*

[FR Doc. 05-7338 Filed 4-12-05; 8:45 am]

BILLING CODE 4160-01-S

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### Request for Nominations for Voting Consumer Representative Members on Public Advisory Committees

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is requesting nominations for voting consumer representatives to serve on its advisory committees that are under the purview of the Center for Drug Evaluation and Research (CDER).

FDA has a special interest in ensuring that women, minority groups, and individuals with disabilities are adequately represented on its advisory

committees and, therefore, encourages nominations of qualified candidates from these groups.

**DATES:** Nominations will be accepted for current vacancies and for those that will or may occur through December 31, 2005. Because vacancies occur on various dates throughout the year, there is no cutoff date for the receipt of nominations.

**ADDRESSES:** All nominations should be sent to the contact person listed in the **FOR FURTHER INFORMATION CONTACT** section of this document.

**FOR FURTHER INFORMATION CONTACT:** Igor Cerny, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, Maryland 20857, 301-827-7001, e-mail: [cerny@cder.fda.gov](mailto:cerny@cder.fda.gov).

**SUPPLEMENTARY INFORMATION:** FDA is requesting nominations for voting consumer representatives to all of its advisory committees identified in section I of this document.

### I. Functions

The functions of advisory committees under the purview of CDER are listed in the following paragraphs.

#### A. Arthritis Advisory Committee

The committee reviews and evaluates data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of arthritis, rheumatism, and related diseases and makes appropriate recommendations to the Commissioner of Food and Drugs (the Commissioner).

#### B. Anti-Infective Drugs Advisory Committee

The committee reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of infectious diseases and disorders and makes appropriate recommendations to the Commissioner.

#### C. Cardiovascular and Renal Drugs Advisory Committee

The committee reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of cardiovascular and renal disorders and makes appropriate recommendations to the Commissioner.

#### D. Dermatologic and Ophthalmic Drugs Advisory Committee

The committee reviews and evaluates available data concerning the safety and